Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 6/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.37 |
| ▸ | ZDHHC20 | Q5W0Z9 | 3/20 | 0.36 |
| ▸ | ZDHHC2 | Q9UIJ5 | 2/20 | 0.36 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | ADH4 | P08319 | 1/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.31 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.31 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.31 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239128 | 0.77 | DNM1 (0.50) | TSHRDNM1ADH1CADH1AADH4 | |
| SCHEMBL4140633 | 0.76 | TSHR (0.44) | TSHRALDH1A1FAAHDNM1ZDHHC20 | |
| SCHEMBL14812559 | 0.76 | TSHR (0.44) | TSHRALDH1A1FAAHDNM1ZDHHC20 | |
| SCHEMBL788690 | 0.76 | TSHR (0.44) | TSHRALDH1A1FAAHDNM1ZDHHC20 | |
| SCHEMBL811342 | 0.75 | DNM1 (0.55) | TSHRDNM1ADH1CADH1AADH4 | |
| SCHEMBL4453840 | 0.75 | DNM1 (0.55) | TSHRDNM1ADH1CADH1AADH4 | |
| SCHEMBL4755851 | 0.74 | TSHR (0.48) | TSHRALDH1A1FAAHDNM1ZDHHC20 | |
| SCHEMBL8423278 | 0.74 | TSHR (0.48) | TSHRALDH1A1FAAHDNM1ZDHHC20 | |
| SCHEMBL22157373 | 0.74 | TSHR (0.48) | TSHRALDH1A1FAAHDNM1ZDHHC20 | |
| SCHEMBL22157437 | 0.74 | TSHR (0.42) | TSHRALDH1A1FAAHDNM1ZDHHC20 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180369323-A1 | MODULATION OF HEPATITIS B VIRUS CCCDNA TRANSCRIPTION | UNIV DREXEL (US) | 2018-12-27 | — | — | US | disclosed |
| US-9301950-B2 | Adamantane analogs | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2016-04-05 | — | — | US | disclosed |
| CN-104507488-A | Modulation of hepatitis b virus cccdna transcription | UNIV DREXEL | 2015-04-08 | — | — | CN | disclosed |
| US-8440720-B2 | Methods of use of antiviral compounds | INFLUMEDIX, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| US-20120270917-A1 | ADAMANTANE ANALOGS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-10-25 | — | — | US | disclosed |
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | INFLUMEDIX, INC. | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110065766-A1 | METHODS OF USE OF ANTIVIRAL COMPOUNDS | MAVS, SLC30A5, HAVCR2 | TSHR 3751/4885ALDH1A1 3877/4885FAAH 2661/4885 |
| US-20120270917-A1 | ADAMANTANE ANALOGS | HAVCR2, ADORA2A, ADORA1 | TSHR 1052/4885ALDH1A1 1161/4885FAAH 1924/4885 |
| US-20180369323-A1 | MODULATION OF HEPATITIS B VIRUS CCCDNA TRANSCRIPTION | DNMT1, DNMT3B, HDAC1 | TSHR 2652/4885ALDH1A1 2773/4885FAAH 4012/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.